Several translational animal models have been described assessing intra-arterial (IA) treatments for malignant gliomas. We describe the first endovascular animal model that allows testing of IA drug delivery as a first-line treatment, which is difficult to do in actual patients. We report a unique protocol for vascular access and IA delivery in the rat model that, unlike prior reports, does not require direct puncture and opening of proximal cerebrovasculature which carries risk of ischemia in the animal brain post-delivery.
Methods
Wistar rats underwent left femoral artery catherization with a Balt Magic 1.2F catheter or Marathon Flow directed 1.5F Microcatheter with an Asahi Chikai 0.008 micro-guidewire which was navigated to the left internal carotid artery under x-ray. 25% mannitol was administered to test blood brain barrier breakdown (BBBB). Additional rats were implanted with C6 glioma cells in the left frontal lobe. C6 Glioma-Implanted Rats (C6GRs) were monitored for overall survival and tumor growth. Tumor volumes from MRI images were calculated utilizing 3D slicer. Additional rats underwent femoral artery catheterization with Bevacizumab, carboplatin, or irinotecan injected into the left internal carotid artery to test feasibility and safety.
Results
A successful endovascular access and BBBB protocol was established. BBBB was confirmed with positive Evans blue staining. 10 rats were successfully implanted with C6 gliomas with confirmed growths on MRI. Overall survival was 19.75 ± 2.21 days. 5 rats were utilized for the development of our femoral catheterization protocol and BBBB testing. With regards to IA chemotherapy dosage testing, control rats tolerated targeted 10 mg/kg of bevascizumab, 2.4 mg/kg of carboplatin, and 15 mg/kg of irinotecan IA ICA injections without any complications.
Conclusions
We present the first endovascular IA rat glioma model that allows selective catheterization of the intracranial vasculature and assessment of IA therapies for gliomas without need for access and sacrifice of proximal cerebrovasculature.
BoockvarJ.Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma. 2011.
2.
BoockvarJ.Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA. 2011.
3.
BoockvarJ.Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA. 2010.
4.
BoockvarJ.Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM. 2013.
5.
EllisJABanuMHossainSS, et al.Reassessing the role of intra-arterial drug delivery for glioblastoma multiforme treatment. J Drug Deliv2015; 2015: 405735.
6.
HanifFMuzaffarKPerveenK, et al.Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev2017; 18: 3.
7.
BlanchardJMathieuDPatenaudeY, et al.MR-pathological comparison in F98-Fischer glioma model using a human gantry. Can J Neurol Sci2006; 33: 86–91.
8.
BranleFLefrancFCambyI, et al.Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer: Interdisciplinary International Journal of the American Cancer Society2002; 95: 641–655.
9.
DemeuleMRéginaAAnnabiB, et al.Brain endothelial cells as pharmacological targets in brain tumors. Mol Neurobiol2004; 30: 157–183.
10.
GiakoumettisDKritisAForoglouN. C6 cell line: the gold standard in glioma research. Hippokratia2018; 22: 105.
11.
KruseCAMitchellDHKleinschmidt-DeMastersBK, et al.Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neuro-Oncol1993; 15: 97–112.
12.
ParsaATChakrabartiIHurleyPT, et al.Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery2000; 47: 993–999. discussion 999.
13.
RadaelliECerutiRPattonV, et al.Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol2009; 24: 879–891.
14.
LiuSZhangS-mJuR-j, et al.Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. Eur J Pharm Sci2017; 106: 185–197.
15.
QinTWangCChenX, et al.Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma. Toxicol Appl Pharmacol2015; 286: 112–123.
16.
XuHChenQWangH, et al.Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II. J Exp Clin Cancer Res2016; 35: 1–10.
17.
BoockvarJATsiourisAJHofstetterCP, et al.Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. J Neurosurg2011; 114: 624–632.
18.
BurkhardtJ-KRiinaHShinBJ, et al.Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg2012; 77: 130–134.
19.
D’AmicoRSKhatriDReichmanN, et al.Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going. J Neuro-Oncol2020; 147: 261–278.
20.
FrenchJWestPVon AmerongenF, et al.Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J Neurosurg1952; 9: 378–389.
21.
PatelNVWongTFralinSR, et al.Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. J Neuro-Oncol2021; 155: 117–124.
22.
WilsonCB. Chemotherapy of brain tumors by continuous arterial infusion. Surgery1964; 55: 640–653.
23.
CosoloWChristophidisN. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats. Cancer Res1987; 47: 6225–6228.
24.
InoueTFukuiMNishioS, et al.Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. J Neurosurg1987; 66: 256–263.
25.
LiuH-LHuaM-YChenP-Y, et al.Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology2010; 255: 415–425.
26.
MeiJChengYSongY, et al.Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imaging–guided focused ultrasound. J Ultrasound Med2009; 28: 871–880.
27.
AskoxylakisVArvanitisCDWongCS, et al.Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors. Adv Drug Delivery Rev2017; 119: 159–174.
HiesigerEVoorhiesRBaslerG, et al.Opening the blood–brain and blood–tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol1986; 19: 50–59.
30.
McDannoldNClementGTBlackP, et al.Transcranial magnetic resonance imaging–guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery2010; 66: 323–332.
31.
AssiHCandolfiMLowensteinPR, et al.Rodent glioma models: intracranial stereotactic allografts and Xenografts. Neuromethods2012; 77: 229–243. 20120313..
32.
FedorovABeichelRKalpathy-CramerJ, et al.3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging2012; 30: 1323–1341.
33.
BarthRFKaurB. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neuro-Oncol2009; 94: 299–312.
34.
JacobsVLValdesPAHickeyWF, et al.Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN neuro2011; 3: AN20110014.
35.
PfeifferSHerschmanHLightbodyJ, et al.Synthesis by a clonal line of rat glial cells of a protein unique to the nervous system. J Cell Physiol1970; 75: 329–339.
36.
SchmidekHHNielsenSLSchillerAL, et al.Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg1971; 34: 335–340.
37.
TownerRAGillespieDLSchwagerA, et al.Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. Neuro Oncol2013; 15: 330–340.
38.
AtzoriMGTentoriLRuffiniF, et al.The anti–vascular endothelial growth factor Receptor-1 monoclonal antibody D16F7 inhibits glioma growth and angiogenesis in vivo. J Pharmacol Exp Ther2018; 364: 77–86.
39.
DagıstanYKaracaIBozkurtER, et al.Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. Acta Cir Bras2012; 27: 383–387.
40.
WangGDaiFYuK, et al.Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways. Int J Oncol2015; 46: 1739–1747.
41.
ZhangXGuoMShenL, et al.Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model. Photodiagn Photodyn Ther2014; 11: 603–612.
42.
BurkhardtJKRiinaHShinB, et al.Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol2011; 17: 286–295.
43.
NambaHKobayashiSIwadateY, et al.Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99m-hexamethyl propyleneamine oxime—technical note—. Neurol Med Chir (Tokyo)1994; 34: 832–835.
44.
ChenSRChenMMEneC, et al.Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors. J Neurointerv Surg2022; 14: 533–538.
45.
FaltingsLKulasonKOPatelNV, et al.Rechallenging recurrent glioblastoma with intra-arterial bevacizumab with blood brain–barrier disruption results in radiographic response. World Neurosurg2019; 131: 234–241.
46.
ErdlenbruchBSchinkhofCKuglerW, et al.Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol2003; 139: 685–694.
47.
JoshiSEllisJAEmalaCW. Revisiting intra-arterial drug delivery for treating brain diseases or is it “déjà-vu, all over again”?J Neuroanaesth Crit Care2014; 1: 108–115.
48.
KimMBaroneTAFedtsovaN, et al.A murine model of targeted infusion for intracranial tumors. J Neuro-Oncol2016; 126: 37–45.
49.
MoritaKTanakaRKakinumaK, et al.Combination therapy of rat brain tumours using localized interstitial hyperthermia and intra-arterial chemotherapy. Int J Hyperthermia2003; 19: 204–212.
50.
AksoyDBammerRMlynashM, et al.Magnetic resonance imaging profile of blood–brain barrier injury in patients with acute intracerebral hemorrhage. J Am Heart Assoc2013; 2: e000161.
51.
KumagaiKHorikawaMYamadaK, et al.Transtail artery access in rats: a new technique for repeatable selective angiography. J Vasc Interv Radiol2020; 31: 678–681. e674.
